Kit for the preparation of technetium tc-99m albumin aggregated - Biologic Drug Details

Summary for kit for the preparation of technetium tc-99m albumin aggregated

Tradenames:	4
High Confidence Patents:	0
Applicants:	3
BLAs:	4
Suppliers: see list	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for kit for the preparation of technetium tc-99m albumin aggregated Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for kit for the preparation of technetium tc-99m albumin aggregated Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Cis Bio International	PULMOTECH MAA	kit for the preparation of technetium tc-99m albumin aggregated	For Injectable Suspension	210089	3,749,556	1991-08-19	DrugPatentWatch analysis and company disclosures
Cis Bio International	PULMOTECH MAA	kit for the preparation of technetium tc-99m albumin aggregated	For Injectable Suspension	210089	4,024,233	1994-07-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for kit for the preparation of technetium tc-99m albumin aggregated Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for Technetium Tc-99m Albumin Aggregated Kit

Last updated: March 12, 2026

What is the Current Market Size and Growth for Tc-99m Albumin Aggregate Kits?

The global market for radiopharmaceuticals, including kits for preparing technetium Tc-99m albumin aggregated (AA), is valued at approximately USD 1.2 billion as of 2022. The compound, used predominantly in imaging procedures such as lung perfusion scans, accounts for a significant share within the nuclear medicine sector. The compound’s market is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 through 2028, driven by rising demand for non-invasive diagnostic procedures.

What are the Key Market Drivers?

Increasing Prevalence of Cardiopulmonary Diseases

Lung perfusion scans utilizing Tc-99m AA are standard in detecting pulmonary embolism. Rising incidence of chronic obstructive pulmonary disease (COPD) and pulmonary hypertension directly increases demand for lung perfusion imaging. The CDC reports COPD affects over 16 million Americans, with the global burden escalating.

Growing Adoption of Nuclear Medicine Procedures

Advances in imaging technology, including hybrid SPECT-CT systems, enhance diagnostic capabilities and expand indications for radiopharmaceuticals, including Tc-99m AA. Governments investing in nuclear medicine infrastructure further accelerate adoption.

Technological Advancements

Enhanced kit formulations offering superior stability, higher yields, and reduced preparation time bolster market growth. Companies investing in R&D for next-generation kits can gain competitive advantages.

What are the Market Challenges?

Supply Chain Constraints

The reliance on molybdenum-99 generators affects supply stability due to aging infrastructure and geopolitical issues, impacting availability of Tc-99m radiotracers.

Regulatory Approvals and Reimbursement Policies

Certifications from agencies like the U.S. FDA and EMA are mandatory for marketing radiopharmaceutical kits. Variable reimbursement policies create pricing pressures, limiting profit margins for manufacturers.

Competition and Patent Expirations

Established players like GE Healthcare, Cardinal Health, and Jubilant Radiopharma hold significant market shares. Expiry of patents and patent expirations for older formulations open pathways for generic entrants, potentially reducing market prices.

What is the Financial Trajectory for Kit Manufacturers?

Revenue Forecasts

Manufacturers reporting revenues in the Tc-99m AA kit segment expect a steady growth trajectory. For example, revenue from leading global suppliers increased by approximately 3.5% annually from 2018 to 2022 [1]. The compounded growth is projected to accelerate as adoption expands.

Cost Structure and Profit Margins

High manufacturing costs stem from sourcing radioisotopes, stringent quality controls, and regulatory compliance. Gross margins typically range from 40-55%. Economies of scale and process optimization could improve margins.

Investment and R&D Spending

Major industry players allocate approximately 7-10% of annual revenue toward R&D to innovate kit formulations or enhance stability. Investment in supply chain resilience, especially post-pandemic, also influences capital deployment.

Market Entry and Licensing

New entrants face barriers related to regulatory approval (average approval time: 1.5-2 years), establishing supply chains, and building client relationships. Licensing fees and partnerships with radiopharmacies are common strategies.

How Does Industry Competition Influence Financial Outlook?

The market features a few dominant firms and several regional players. Market share distribution as of 2022:

Company	Market Share (%)	Key Strengths
GE Healthcare	35	Established distribution, R&D capabilities
Jubilant Radiopharma	20	Focused on innovation and regional expansion
Cardinal Health	15	Supply chain efficiency
Others	30	Localized offerings, niche specialties

The high concentration indicates that major firms hold pricing power and shape market trends.

Regulatory and Policy Environment

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulate kit approval processes. The submission process involves demonstrating safety, efficacy, and manufacturing quality. Average approval timelines are approximately 18-24 months.

Reimbursement remains a critical factor. In the U.S., Medicare and private insurers reimburse lung perfusion scans, influencing hospital procurement decisions. Policy shifts toward value-based care favor the adoption of more accurate imaging agents, including Tc-99m AA kits.

Conclusion

The market for Tc-99m albumin aggregate kits exhibits steady growth fueled by increased nuclear medicine use, technological advances, and rising prevalence of cardiopulmonary diseases. Supply chain stability and regulatory considerations remain significant factors influencing financial outcomes. Major companies focus on R&D and supply chain resilience to sustain competitiveness. While revenues are expected to grow moderately, margins depend heavily on regulatory approval, competitive dynamics, and reimbursement policies.

Key Takeaways

• Market value was approximately USD 1.2 billion in 2022, with a CAGR of 4.2% (2023-2028).
• Lung perfusion imaging demand drives growth, linked to COPD and pulmonary hypertension prevalence.
• Supply chain disruptions and regulatory hurdles pose risks; competition among established firms is intense.
• Leading players hold dominant market shares; new entrants face high barriers but can capitalize on innovation.
• Reimbursement policies significantly impact revenue trajectories, especially in North America and Europe.

FAQs

1. What are the primary clinical indications for Tc-99m albumin aggregate kits?
   They are primarily used for lung perfusion imaging to detect pulmonary embolism and evaluate pulmonary hypertension.

2. Which regions represent the largest markets for these kits?
   North America accounts for the largest share, followed by Europe and Asia-Pacific, reflecting healthcare infrastructure and diagnostic demand.

3. How do regulatory approvals influence market entry?
   Approval processes involve demonstrating safety and efficacy, typically taking 1.5 to 2 years, which can delay market entry and affect financial planning.

4. What are the main competitors in the Tc-99m AA kit market?
   GE Healthcare, Jubilant Radiopharma, and Cardinal Health lead the market in terms of sales and distribution.

5. What is the impact of supply chain issues on the market?
   Disruptions in molybdenum-99 supply affect availability of Tc-99m radiotracers, constraining market growth and causing price fluctuations.

---

References

[1] Industry reports and company disclosures (2022). "Global Radiopharmaceutical Market Analysis."